Effectiveness and safety of dapagliflozin in real-life patients: data from the DAPA-RWE Spanish multicentre study

Article Details

Authors
Cristóbal Morales, Juan Francisco Merino-Torres, Paloma Moreno-Moreno, María Lainez, Iñigo Tejado, Alfredo Yoldi, Sonsoles Gutiérrez Medina, Alfonso Soto, Manuel A Botana, Virginia Bellido, Irene Caballero

Article Type
Original Research

DOI
10.7573/dic.2021-11-5

Related Articles

Article Page

Abstract

Background: This study aims to evaluate dapagliflozin in patients with type 2 diabetes (T2D) in clinical practice in Spain.

Methods: This is a retrospective study including adults with T2D under stable antidiabetic therapy, with either dapagliflozin or sitagliptin ≥6 months, before inclusion. Data about the effectiveness and safety of dapagliflozin are presented.

Results: A total of 594 patients (61.8±9.9 years, 21.7% cardiovascular disease) were included. After 6 months, HbA1c, weight, blood pressure, urine albumin-to-creatinine ratio and uric acid significantly decreased (1.63%, 2.88 kg, 4.82/2.70 mmHg, −17.38 mg/g and −0.30 mg/dL, respectively), whereas glomerular filtration rate and haematocrit significantly increased (3.72 mL/min/1.73 m2 and 1.8%, respectively). No cases of hypoglycaemia, diabetic ketoacidosis, Fournier gangrene, fractures or amputations were reported.

Conclusion: Thus, dapagliflozin provides a comprehensive cardiometabolic protection in patients with T2D.

Keywords: clinical practice, dapagliflozin, diabetes, HbA1c, weight.

Citation: Morales C, Merino-Torres JF, Moreno-Moreno P, Lainez M, Tejado I, Yoldi A, Gutiérrez Medina S, Soto A, Botana MA, Bellido V, Caballero I. Effectiveness and safety of dapagliflozin in real-life patients: data from the DAPA-RWE Spanish multicentre study. Drugs Context. 2022;11:2021-11-5. https://doi.org/10.7573/dic.2021-11-5

Contributions: All authors contributed equally to the preparation of this manuscript. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosure and potential conflicts of interest: This work was supported by AstraZeneca. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2022/01/dic.2021-11-5-COI.pdf

Acknowledgements: The authors thank the investigators involved in the study. Writing assistance was provided by Content Ed Net, Madrid, Spain.

Funding declaration: This work was supported by AstraZeneca.

Copyright: Copyright © 2022 Morales C, Merino-Torres JF, Moreno-Moreno P, Lainez M, Tejado I, Yoldi A, Gutiérrez Medina S, Soto A, Botana MA, Bellido V, Caballero I. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2022 Morales C, Merino-Torres JF, Moreno-Moreno P, Lainez M, Tejado I, Yoldi A, Gutiérrez Medina S, Soto A, Botana MA, Bellido V, Caballero I. https://doi.org/10.7573/dic.2021-11-5. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/effectiveness-and-safety-of-dapagliflozin-in-real-life-patients-data-from-the-dapa-rwe-spanish-multicentre-study

Correspondence: Irene Caballero, Unidad de Diabetes y Obesidad Hospital Vithas Sevilla & Hospital Universitario Virgen Macarena, Spain. Email: irenecaballerom@hotmail.com

Provenance: Submitted; externally peer reviewed.

Submitted: 17 November 2021; Accepted: 17 January 2022; Publication date: 17 February 2022.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editorial office editorial@drugsincontext.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF